• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

"GLP-1 agonists ... weight using GLP-1 agonist drugs but are planning to discontinue the treatment. RDX-002, Response Pharmaceuticals’ lead candidate, is an investigational first-in-class, potent, ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

such prior studies on the effects of GLP-1 receptor agonists and SGLT2 inhibitors on varying severities of COPD exacerbations have been valuable but “were limited by small populations ...